ANSWER: C

Rationale:

This patient has classic hypertensive nephrosclerosis — CKD resulting from decades of uncontrolled hypertension in the context of likely underlying susceptibility. The bilaterally small echogenic kidneys represent chronic parenchymal scarring from sustained hypertensive glomerular injury, not acute disease. The severely elevated UACR of 1,240 mg/g reflects the degree of glomerular injury and is both a marker of disease severity and an independent driver of further CKD progression through the pressure-proteinuria-fibrosis axis. RAAS activation in this setting is secondary — ischemic nephrons release renin, sustaining angiotensin II levels that perpetuate hypertension and efferent arteriolar constriction. Doppler excluded renal artery stenosis.

• Option A: Option A is incorrect because primary FSGS cannot be diagnosed from clinical features alone and should not be assumed as the first diagnosis without evaluation — hypertensive nephrosclerosis is by far the more common cause of CKD with moderate proteinuria in a hypertensive African American woman, and empirical RAAS inhibition is appropriate before considering biopsy.
• Option B: Option B is incorrect because the Doppler ultrasound has already excluded significant renal artery stenosis, removing the primary concern about bilateral RAS; the bilaterally small kidneys here represent chronic parenchymal disease, not ongoing ischemia from arterial stenosis.
• Option D: Option D is incorrect because there is no basis for diagnosing diabetic nephropathy without evidence of diabetes — attributing the presentation to diabetic nephropathy before checking HbA1c inverts the diagnostic process.
• Option E: Option E is incorrect because the UACR of 1,240 mg/g is not a non-specific finding requiring only BP control — it is a major independent driver of CKD progression that requires specific RAAS-based antiproteinuric therapy beyond systemic pressure reduction.

ANSWER: A

Rationale:

A 29% creatinine rise is within the acceptable hemodynamic range (up to 30–35%) for RAAS inhibitor initiation and reflects the intended reduction in intraglomerular pressure — not nephrotoxicity. The 34% UACR reduction from 1,240 to 820 mg/g at 4 weeks confirms a favorable antiproteinuric response that predicts long-term renoprotection and should be preserved. Potassium of 5.2 mEq/L is elevated but does not meet the threshold for drug discontinuation — dietary potassium restriction (reduce bananas, potatoes, tomatoes, citrus) and repeat measurement in 2 weeks are appropriate. The correct action is to continue losartan at the current dose and monitor closely.

• Option B: Option B is incorrect because a 29% creatinine rise is not nephrotoxicity — it is the expected hemodynamic response to efferent arteriolar dilation; discontinuing in a patient with an excellent antiproteinuric response would forfeit the renoprotective benefit.
• Option C: Option C is incorrect because adding lisinopril to losartan constitutes dual RAAS blockade, which is explicitly contraindicated in CKD — the VA NEPHRON-D trial demonstrated excess AKI and hyperkalemia without renal benefit from this combination.
• Option D: Option D is incorrect because a 29% rise does not exceed the acceptable threshold of 30–35%; holding the drug is not indicated, and doing so would interrupt the established antiproteinuric response without clinical justification.
• Option E: Option E is incorrect because adding spironolactone to losartan in a patient with eGFR 32 and potassium already at 5.2 mEq/L carries a high risk of dangerous hyperkalemia — combining two potassium-retaining agents in this context is not appropriate management.

ANSWER: D

Rationale:

At eGFR 28 (transitioning into CKD stage 4), hydrochlorothiazide has substantially reduced diuretic efficacy. Thiazide diuretics require active tubular secretion to reach their site of action (the sodium-chloride cotransporter in the distal convoluted tubule), and at eGFR below 30 mL/min/1.73m2, reduced nephron mass and impaired tubular secretion limit this access significantly. Switching to furosemide (or torsemide for superior bioavailability) — which acts on the NKCC2 cotransporter in the thick ascending limb — provides far greater natriuretic capacity at this eGFR and is the appropriate diuretic transition at this stage. This is a critical pharmacological decision point in CKD progression. Option B identifies a real pharmacological principle (chlorthalidone retaining more efficacy than HCTZ at lower eGFR, supported by the CLICK trial), but at eGFR 28 the patient is at the lower boundary of the CLICK trial eGFR range and transitioning to a loop diuretic is the more appropriate step — chlorthalidone is better suited for stage 3 CKD rather than the CKD stage 4 threshold this patient is approaching.

• Option A: Option A is incorrect because dual RAAS blockade (ACEi plus ARB) is contraindicated in CKD regardless of the patient population comparison — the VA NEPHRON-D findings apply broadly and the risk of AKI and hyperkalemia is not mitigated by the patient's specific eGFR compared to the trial population.
• Option C: Option C is incorrect because hydralazine as a fourth-line agent is not the standard next step in CKD-related uncontrolled hypertension — a diuretic class transition is the more pharmacologically targeted and evidence-appropriate intervention.
• Option E: Option E is incorrect because while bisoprolol has a role in CKD, there is no evidence base establishing beta-blockers as the preferred fourth agent in non-HFrEF CKD resistant hypertension; the diuretic transition is the mechanistically correct priority when volume-dependent hypertension is likely contributing.

ANSWER: B

Rationale:

RAAS inhibitors retain a role in hemodialysis patients for cardiovascular protection and residual renal function preservation. The RAAS system is not fully suppressed by dialysis — renin secretion from ischemic native kidneys continues, angiotensin II levels remain elevated interdialytically, and cardiovascular risk remains extremely high in dialysis patients. Among ARBs, the choice of agent matters pharmacokinetically: losartan and its active metabolite EXP-3174 have moderate protein binding but some dialyzability; candesartan and telmisartan are more highly protein-bound, lipophilic, and not significantly removed by hemodialysis, providing more consistent blood levels across the interdialytic period without the post-dialysis concentration dip that may occur with more dialyzable agents. Switching to candesartan or telmisartan is pharmacokinetically rational in this setting.

• Option A: Option A is incorrect because the RAAS is not suppressed by ultrafiltration — renin secretion from the native kidneys continues in ESRD, angiotensin II remains a cardiovascular risk driver, and RAAS inhibitors continue to provide cardiovascular protection in dialysis patients.
• Option C: Option C is incorrect in its pharmacokinetic claim — while losartan is highly protein-bound, the dialyzability of RAAS inhibitors varies within the class and the statement that dialysis does not alter losartan pharmacokinetics is an oversimplification that is not entirely accurate.
• Option D: Option D is incorrect because both CCBs and RAAS inhibitors have roles in dialysis patients; the claim that CCBs are the "only" class with proven benefit is an unsupported absolute, and RAAS inhibitors are not specifically associated with excess mortality from dialysis hypotension in the clinical evidence base.
• Option E: Option E is incorrect because the pharmacokinetic rationale for holding RAAS inhibitors on dialysis days to avoid hypotension is not standard clinical practice and is not supported by current guidelines; the preferred approach is to select a less dialyzable agent and continue consistently. CASE 2 — A 47-year-old man with type 2 diabetes diagnosed 8 years ago and hypertension presents for a follow-up visit. He has been on metformin 1000 mg twice daily, empagliflozin 10 mg daily, and amlodipine 5 mg daily. His BP is 146/88 mmHg. Labs: eGFR 62 mL/min/1.73m2, creatinine 1.28 mg/dL, potassium 4.1 mEq/L, HbA1c 7.6%, UACR 380 mg/g. He has never been on a RAAS inhibitor. Cardiovascular history: no established atherosclerotic cardiovascular disease (ASCVD). He is otherwise healthy.

ANSWER: E

Rationale:

The absence of a RAAS inhibitor is the most critical gap in this patient's management. RAAS inhibition is the cornerstone of renoprotection in diabetic CKD with significant albuminuria — it is the only pharmacological class with Level A evidence for slowing CKD progression through mechanisms partially independent of systemic BP reduction (efferent arteriolar dilation, direct antiproteinuric and anti-fibrotic effects). His UACR of 380 mg/g substantially exceeds the 300 mg/g threshold at which RAAS inhibition is strongly recommended by KDIGO 2021 regardless of BP control status. Empagliflozin provides complementary renoprotection but does not substitute for RAAS inhibition — the two classes work through mechanistically distinct and additive pathways. Starting an ACE inhibitor or ARB at low dose with uptitration is the highest-priority pharmacological intervention for this patient.

• Option A: Option A is incorrect because while HbA1c optimization is important, his glycemic control at 7.6% is reasonably close to target and does not represent a greater management gap than the complete absence of RAAS inhibition in a patient with severely elevated albuminuria.
• Option B: Option B is incorrect because while statin therapy is important for cardiovascular risk reduction in this patient, the absence of an antiproteinuric renoprotective agent in a patient with UACR 380 mg/g represents a more specifically addressable and immediately impactful gap in management.
• Option C: Option C is incorrect because the priority in uncontrolled hypertension with proteinuric CKD is to add RAAS inhibition first — which addresses both BP and proteinuria — not to add any third agent arbitrarily.
• Option D: Option D is incorrect because empagliflozin 10 mg is the established renoprotective dose used in EMPA-KIDNEY and EMPA-REG OUTCOME; there is no evidence that 25 mg provides superior renal outcomes compared to 10 mg, and the labeled renoprotective indication uses the 10 mg dose.

ANSWER: C

Rationale:

The 21% creatinine rise is the expected and intended hemodynamic consequence of ramipril's efferent arteriolar dilation — a pharmacological effect that is both predicted and beneficial. Angiotensin II normally maintains intraglomerular pressure by preferentially constricting the efferent arteriole; when ACE inhibition removes this efferent constriction, intraglomerular hydraulic pressure falls and GFR decreases modestly. This is the mechanism of action responsible for the antiproteinuric effect and the long-term renoprotection demonstrated in landmark trials. The 45% UACR reduction powerfully confirms that the drug is working as intended and provides evidence of meaningful renoprotective effect. The creatinine will stabilize at this new hemodynamic steady state. The correct explanation to the patient is that the modest creatinine rise is a sign the drug is working, not harming, his kidneys.

• Option A: Option A is incorrect because ACE inhibitors do not cause direct tubular damage through bradykinin accumulation — cough is the most common bradykinin-related adverse effect; the creatinine rise is hemodynamic, not nephrotoxic.
• Option B: Option B is incorrect because the mechanism described (systemic hypotension reducing perfusion below autoregulatory threshold) would not produce a modestly stable 21% creatinine rise — this mechanism would cause a more precipitous and symptomatic decline, not the expected hemodynamic steady state; and his BP of 132/80 mmHg is not aggressively low.
• Option D: Option D is incorrect because acute interstitial nephritis from ACE inhibitors is a rare and distinct entity that typically presents with additional features (eosinophilia, fever, rash, sterile pyuria, eosinophiluria) and does not present as an isolated asymptomatic modest creatinine rise in the context of a 45% reduction in proteinuria.
• Option E: Option E is incorrect because ACE inhibitors do not inhibit tubular creatinine secretion through organic cation transporter blockade — this is a mechanism relevant to trimethoprim and some other drugs, not ACE inhibitors; ramipril's creatinine rise is hemodynamic.

ANSWER: A

Rationale:

This patient is an excellent candidate for finerenone addition. The FIGARO-DKD trial enrolled patients with type 2 diabetic CKD and UACR as low as 30 mg/g, demonstrating significant reduction in the cardiovascular composite endpoint with finerenone on background RAAS inhibition — explicitly covering patients with moderately elevated albuminuria like this patient's UACR of 140 mg/g. His potassium of 4.3 mEq/L is comfortably below the 5.0 mEq/L prerequisite threshold for safe initiation. The combination of RAAS inhibitor plus SGLT2 inhibitor plus finerenone — the emerging triple renoprotective strategy — targets three mechanistically distinct pathways: efferent arteriolar dilation and RAAS-mediated fibrosis (ramipril), tubuloglomerular feedback restoration and metabolic renoprotection (empagliflozin), and aldosterone receptor-mediated inflammation and fibrosis (finerenone).

• Option B: Option B is incorrect because the triple combination has been studied in clinical contexts — the FIDELIO-DKD and FIGARO-DKD trials both allowed SGLT2 inhibitor use in a proportion of participants — and finerenone is not contraindicated with SGLT2 inhibitors; the combination has an acceptable hyperkalemia profile in appropriately selected patients.
• Option C: Option C is incorrect because the FIGARO-DKD trial explicitly demonstrated benefit down to UACR 30 mg/g, and no 300 mg/g minimum threshold for finerenone is specified in current clinical guidance.
• Option D: Option D is incorrect because finerenone and empagliflozin have mechanistically distinct anti-fibrotic effects — finerenone acts through selective MRA blockade of aldosterone-mediated nuclear factor activation and fibrogenic gene expression, while empagliflozin's anti-fibrotic effects operate through NLRP3 inflammasome suppression and metabolic pathways; they are complementary, not redundant.
• Option E: Option E is incorrect because current evidence supports combining both agents rather than choosing one — guidelines recommend both classes as additive renoprotective interventions in eligible patients, not as alternatives.

ANSWER: D

Rationale:

The perioperative management of this patient's medications requires attention to two specific concerns. First and most critically, empagliflozin must be held at least 3 days before elective surgery — SGLT2 inhibitors cause euglycemic DKA (eKDA) in the perioperative setting through carbohydrate restriction, surgical stress-induced hormonal changes, and relative insulin deficiency; this is a well-established perioperative risk that has led to guideline recommendations from ADA, ESC, and major anesthesia societies. Second, ramipril should be held on the day of surgery — ACE inhibitors are associated with refractory intraoperative hypotension through blunted angiotensin II-mediated vascular responses during anesthesia-induced vasodilation and hemorrhage; holding on the day of surgery and restarting when oral intake and hemodynamics are stable is standard perioperative guidance. Amlodipine is generally continued through the perioperative period as abrupt discontinuation can cause rebound hypertension and it does not contribute significantly to intraoperative hypotension. Finerenone can be continued — there is no specific perioperative concern mandating its cessation.

• Option A: Option A is incorrect because continuing empagliflozin through surgery carries a clinically significant eKDA risk that is well-documented and should not be dismissed.
• Option B: Option B is incorrect because finerenone does not cause perioperative hyperkalemia through the mechanism described, and it is empagliflozin, not finerenone, that represents the critical perioperative safety concern requiring preoperative cessation.
• Option C: Option C is incorrect because empagliflozin must also be held — the eKDA risk is the dominant perioperative safety concern for this patient and is not addressed by holding only ramipril and amlodipine.
• Option E: Option E is incorrect because holding all four medications for 5 days is not necessary or standard — amlodipine and finerenone have no specific perioperative indication for discontinuation, and abrupt amlodipine withdrawal can cause rebound hypertension; a selective and targeted approach is appropriate rather than a blanket medication holiday. CASE 3 — A 38-year-old woman with a 6-year history of systemic lupus erythematosus (SLE) presents with hypertension and CKD discovered on routine monitoring. She is on hydroxychloroquine 400 mg daily and mycophenolate mofetil (MMF) 1500 mg twice daily for SLE. BP is 152/94 mmHg. Labs: creatinine 1.9 mg/dL, eGFR 38 mL/min/1.73m2, potassium 4.3 mEq/L, UACR 2,100 mg/g. Urinalysis: 3+ protein, 2+ blood, red cell casts present. Complement C3 and C4 are low. Anti-dsDNA antibodies are highly elevated. She has not been on any antihypertensive therapy.

ANSWER: B

Rationale:

The combination of red cell casts, severely elevated UACR (2,100 mg/g), active serologies (low complement, elevated anti-dsDNA), and CKD in an SLE patient constitutes an active lupus nephritis flare — most likely proliferative (class III or IV) given the nephritic sediment with red cell casts. This diagnosis fundamentally changes the pharmacological approach compared to hypertensive nephrosclerosis. In hypertensive nephrosclerosis, RAAS inhibition addresses both BP and the pathological mechanism driving progression. In lupus nephritis, the immune-mediated glomerular injury — immune complex deposition activating complement and triggering proliferative glomerulonephritis — requires immunosuppressive induction therapy (cyclophosphamide or rituximab, together with corticosteroids) as the primary disease-modifying intervention; RAAS inhibition is essential as adjunctive therapy for BP control and proteinuria reduction but cannot halt the immunological process alone.

• Option A: Option A is incorrect because IgA nephropathy does not present with red cell casts, low complement, and elevated anti-dsDNA — these are specific markers of immune complex-mediated disease in SLE; the clinical constellation is classic for lupus nephritis.
• Option C: Option C is incorrect because thrombotic microangiopathy from antiphospholipid syndrome presents with microangiopathic hemolytic anemia, thrombocytopenia, and schistocytes — not red cell casts and massively elevated UACR; and a BP of 152/94 mmHg does not constitute a hypertensive emergency.
• Option D: Option D is incorrect because membranous nephropathy (LN class V) presents with a nephrotic pattern (heavy proteinuria, hypoalbuminemia, edema) and bland urinalysis without red cell casts or an active nephritic sediment; the active sediment here points to proliferative, not membranous, disease.
• Option E: Option E is incorrect because red cell casts and UACR 2,100 mg/g indicate a serious renal manifestation of SLE that requires formal nephrology evaluation and likely renal biopsy — increasing hydroxychloroquine dosing alone is wholly inadequate for a proliferative lupus nephritis presentation.

ANSWER: E

Rationale:

This answer correctly integrates the BP target, the rationale for RAAS inhibition, the impact of corticosteroids on volume, and the appropriate diuretic selection. The BP target is less than 130/80 mmHg (ACC/AHA 2017 CKD guideline, consistent with KDIGO 2021). An ACE inhibitor or ARB is strongly indicated given her UACR of 2,100 mg/g — RAAS inhibition reduces intraglomerular pressure and proteinuria through a mechanism complementary to immunosuppression of the underlying glomerulonephritis. Corticosteroids cause mineralocorticoid-mediated sodium and water retention, commonly producing hypertension and edema that require concurrent diuretic therapy. At eGFR 38 (transitioning into stage 4 territory), furosemide or torsemide is more appropriate than a thiazide whose efficacy is declining. Amlodipine provides additional BP-lowering benefit without adverse renal hemodynamic consequences when used in combination with a RAAS inhibitor. Option D is pharmacologically correct in its reasoning but incomplete — it does not address the specific volume management challenge created by corticosteroid therapy, which is a clinically important consideration in this patient's management that option E covers more completely.

• Option A: Option A is incorrect because a BP target of less than 150/90 mmHg is below the standard of care for this patient — the correct target is less than 130/80 mmHg, and immunosuppression does not alter the recommended BP target in CKD.
• Option B: Option B is incorrect because amlodipine does not raise intraglomerular pressure in the context of immune-mediated glomerular injury — while afferent dilation could theoretically increase intraglomerular pressure, this is not a clinical contraindication to amlodipine in lupus nephritis and the drug is commonly used in this setting.
• Option C: Option C is incorrect because RAAS inhibition is not relatively contraindicated in lupus nephritis — it is specifically indicated for its antiproteinuric benefit, and efferent arteriolar dilation in inflamed glomeruli is the pharmacologically desired mechanism, not a contraindication.

ANSWER: D

Rationale:

The ACE inhibitor-azathioprine interaction is a clinically recognized pharmacological concern. ACE inhibitors reduce angiotensin II-mediated stimulation of erythropoietin synthesis and may suppress hematopoietic progenitor cell activity through bradykinin-related mechanisms; azathioprine causes direct myelosuppression through thiopurine metabolite incorporation into DNA of rapidly dividing cells including bone marrow precursors. The combination can produce additive or synergistic myelosuppression — leukopenia and anemia — that may not be anticipated from either drug alone. This interaction is listed in prescribing information for both drug classes and requires regular complete blood count monitoring when the combination is used. The combination is not absolutely contraindicated — it is used in clinical practice with appropriate monitoring — but the clinician must be aware of the additive myelosuppression risk.

• Option A: Option A is incorrect because lisinopril does not inhibit xanthine oxidase — the clinically relevant xanthine oxidase interaction with azathioprine involves allopurinol, which inhibits xanthine oxidase and dramatically increases azathioprine's myelotoxic metabolite 6-thioguanine levels; this is one of the most important drug interactions in rheumatology, but it involves allopurinol, not ACE inhibitors.
• Option B: Option B is incorrect because furosemide does not share renal transporters with azathioprine's metabolites in a way that causes clinically relevant 6-thiouric acid accumulation — this mechanism is fabricated.
• Option C: Option C is incorrect because amlodipine is a CYP3A4 substrate, not an inhibitor of clinical significance; azathioprine is not primarily metabolized by CYP3A4, so this interaction is pharmacologically inaccurate.
• Option E: Option E is incorrect because the ACE inhibitor-azathioprine myelosuppression risk is a real and clinically documented interaction that requires monitoring.

ANSWER: A

Rationale:

Stopping lisinopril immediately is the single most urgent pharmacological action in this patient. ACE inhibitors (and ARBs) are absolutely contraindicated in pregnancy — classified as FDA Category D in the second and third trimesters (when organogenesis of the fetal kidney occurs) and as Category X by many authorities. The mechanism of teratogenicity is precisely through the pharmacological mechanism of action: ACE inhibitor-mediated suppression of fetal angiotensin II causes impaired fetal renal perfusion and renal tubular dysgenesis, leading to oligohydramnios (reduced amniotic fluid from decreased fetal urine output), skull hypoplasia (from reduced amniotic fluid), limb contractures, pulmonary hypoplasia, and neonatal renal failure. Even first-trimester exposure is associated with cardiovascular and CNS malformations in some studies. The ACE inhibitor must be stopped immediately upon pregnancy recognition and replaced with a pregnancy-safe antihypertensive — labetalol, methyldopa, or extended-release nifedipine are the established safe options for hypertension in pregnancy with CKD. Regarding azathioprine: it is not absolutely contraindicated in pregnancy in the context of SLE — it is frequently used to maintain remission and protect renal function during pregnancy, as the risk of disease flare from stopping immunosuppression outweighs the fetal risk at therapeutic doses.

• Option B: Option B is incorrect because while furosemide requires reassessment in pregnancy, it is not the most urgent priority — the ACE inhibitor poses a far more severe and well-established teratogenic risk that requires immediate action.
• Option C: Option C is incorrect because azathioprine is not absolutely contraindicated in pregnancy for SLE patients — it is commonly continued to maintain disease control, and stopping it risks triggering a lupus flare that would be far more dangerous to mother and fetus than the drug itself.
• Option D: Option D is incorrect because amlodipine is not associated with first-trimester cardiac teratogenicity — nifedipine (a related CCB) is actually an established safe antihypertensive in pregnancy; calcium channel blockers are not contraindicated in pregnancy.
• Option E: Option E is incorrect because while specialist referral is important and appropriate, it is not the first action — the ACE inhibitor must be stopped immediately, before any referral appointment can occur; delaying this action is clinically unacceptable. CASE 4 — A 63-year-old man with CKD stage 3b (eGFR 34), type 2 diabetes, and hypertension presents with BP 168/94 mmHg on three medications: irbesartan 300 mg daily, amlodipine 10 mg daily, and torsemide 20 mg daily. His UACR is 890 mg/g, potassium is 4.8 mEq/L, and creatinine is 2.1 mg/dL (stable). He has been on this regimen for 9 months with inadequate BP control despite confirmed adherence. 24-hour ambulatory BP monitoring confirms truly elevated BP averaging 162/91 mmHg. Renal artery Doppler is normal. He has no secondary causes of hypertension on screening.

ANSWER: C

Rationale:

Spironolactone is the best-evidenced fourth-line agent for resistant hypertension. The PATHWAY-2 trial demonstrated that spironolactone 25–50 mg daily was significantly superior to bisoprolol, doxazosin, and placebo as the fourth drug in patients with true resistant hypertension (confirmed by 24-hour ABPM on three optimized drugs), reducing home systolic BP by approximately 8.7 mmHg more than placebo. The mechanism is compelling — primary or secondary aldosterone excess is present in a significant proportion of resistant hypertension cases, and mineralocorticoid receptor blockade addresses this driver directly. The critical caveat in this patient is the hyperkalemia risk: eGFR 34, potassium 4.8 mEq/L, and concurrent irbesartan create a high-risk context for spironolactone-induced hyperkalemia. Active management — low-potassium diet, close monitoring, and potentially a potassium binder (patiromer or SZC) — is required to enable this beneficial therapy.

• Option A: Option A is incorrect because clonidine, while a reasonable antihypertensive, does not have evidence from dedicated resistant hypertension trials comparable to spironolactone, and its adverse effect profile (rebound hypertension on discontinuation, sedation, dry mouth) makes it less suitable as a first choice for the fourth drug.
• Option B: Option B is incorrect because amiloride, while used in some resistant hypertension protocols, is not the strongest evidence-based choice and carries significant hyperkalemia risk in this patient with eGFR 34 on an ARB; and the claim of proteinuria reduction through BP-independent mechanisms is not established for amiloride in CKD.
• Option D: Option D is incorrect because renal denervation is not guideline-recommended as first-line for all resistant hypertension in CKD before pharmacological escalation — it remains an adjunctive intervention for patients who fail or cannot tolerate pharmacological optimization.
• Option E: Option E is incorrect because torsemide dose escalation is appropriate to consider but should not preclude the addition of a fourth pharmacological class in a patient with truly confirmed resistant hypertension on 24-hour ABPM — this patient already has torsemide in his regimen and the hypertension has been confirmed as resistant by appropriate methodology.

ANSWER: B

Rationale:

SGLT2 inhibitors can and should be initiated at eGFR 31 in this patient with type 2 diabetic CKD and persistent albuminuria on an otherwise optimized regimen. The DAPA-CKD trial enrolled patients down to eGFR 25, and the CREDENCE trial enrolled patients with eGFR as low as 30, with consistent benefit demonstrated across the eGFR subgroups. The current recommended initiation threshold is eGFR ≥20 mL/min/1.73m2 per KDIGO 2022 and most updated guidelines. When SGLT2 inhibitors are started, an initial eGFR dip of approximately 3–5 mL/min/1.73m2 is expected from tubuloglomerular feedback restoration (afferent arteriolar constriction reducing glomerular hyperfiltration) — analogous to the creatinine rise seen with RAAS inhibitor initiation, this is pharmacologically expected and associated with long-term renoprotection, not drug harm. His current eGFR of 31 means an expected dip to approximately 26–28 mL/min/1.73m2 — still above the cessation threshold.

• Option A: Option A is incorrect on multiple counts — SGLT2 inhibitor renoprotection has been demonstrated below eGFR 45 in multiple trials, it is not glucose-dependent, and the initiation threshold is 20, not 45.
• Option C: Option C is incorrect because tubuloglomerular feedback restoration does occur below eGFR 60 — the mechanism operates at the macula densa regardless of overall nephron mass, though its magnitude may differ; an eGFR dip is expected at any eGFR when SGLT2 inhibitors are initiated and should be anticipated.
• Option D: Option D is incorrect because dose halving is not required — the renoprotective dose is 10 mg for both dapagliflozin and empagliflozin across the approved eGFR range; there is no evidence-based dose reduction for the renoprotective indication based on eGFR.
• Option E: Option E is incorrect because the number of antihypertensive agents is not a contraindication to SGLT2 inhibitor addition; the modest BP-lowering effect of SGLT2 inhibitors (3–5 mmHg systolic) does not create an unacceptable hypotension risk when added to a four-drug regimen.

ANSWER: E

Rationale:

Trimethoprim has two well-established and clinically important pharmacological effects on renal laboratory values that are commonly misinterpreted as AKI. First, trimethoprim is an organic cation that competitively inhibits OCT2-mediated tubular creatinine secretion in the proximal tubule — approximately 10–15% of creatinine clearance occurs via tubular secretion, and blocking this pathway raises serum creatinine by 0.1–0.3 mg/dL (or more in patients with CKD where tubular secretion contributes a proportionally larger fraction of total creatinine excretion) without any change in true GFR. This creatinine rise is a pharmacokinetic artifact, not AKI. Second, trimethoprim blocks epithelial sodium channels (ENaC) in the collecting duct through a mechanism identical to amiloride — this reduces sodium reabsorption and simultaneously reduces the electrochemical driving force for potassium excretion, causing hyperkalemia. In this patient already on irbesartan (which raises potassium via reduced aldosterone) and spironolactone (which blocks mineralocorticoid receptors, also raising potassium), trimethoprim's additive ENaC blockade creates a clinically significant hyperkalemia risk that requires potassium monitoring during the TMP-SMX course.

• Option A: Option A is incorrect because sulfonamide crystalluria and obstructive nephropathy occur primarily with high-dose intravenous sulfonamides with inadequate hydration — not with standard oral TMP-SMX for cellulitis; and the time course (5 days) is more consistent with a pharmacokinetic effect on creatinine measurement than progressive tubular obstruction.
• Option B: Option B is incorrect because TMP-SMX does not inhibit CYP3A4 in a clinically significant way, and canagliflozin's tubuloglomerular feedback effect does not produce a 20% creatinine rise when canagliflozin levels are already at steady state.
• Option C: Option C is incorrect because trimethoprim does not competitively displace ARBs from the AT1 receptor — this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect because mast cell degranulation causing hemodynamic AKI from TMP-SMX is a rare anaphylactic reaction with systemic features, not the mechanism of an isolated asymptomatic creatinine rise.

ANSWER: D

Rationale:

Sodium restriction to below 2,000 mg/day is the most directly pharmacologically supported dietary intervention in this patient's management. The interaction between dietary sodium and RAAS inhibitor efficacy is well-established — high sodium intake sustains volume expansion, suppresses RAAS less completely, and maintains intraglomerular pressure through both RAAS-dependent and non-RAAS (pressure-natriuresis) mechanisms, blunting the antiproteinuric response to ARB therapy. Studies have demonstrated that the antiproteinuric benefit of maximum-dose RAAS inhibition on a high-sodium diet can be substantially enhanced by sodium restriction, with some data showing that the combination of moderate-dose RAAS inhibition plus low sodium intake produces greater proteinuria reduction than maximum-dose RAAS inhibition on a high-sodium diet. Protein restriction to 0.6–0.8 g/kg/day in CKD reduces dietary acid load, nitrogen-containing waste generation, and the degree of glomerular hyperfiltration that high protein intake drives.

• Option A: Option A is incorrect because high-protein intake (greater than 1.5 g/kg/day) increases intraglomerular pressure through amino acid-mediated afferent arteriolar dilation and increases nitrogenous waste production — RAAS inhibition and SGLT2 inhibitors do not fully offset these adverse effects, and protein restriction is a complementary renoprotective strategy.
• Option B: Option B is incorrect because while potassium management is important, a restriction below 1,500 mg/day is unnecessarily severe and not the most pharmacologically important dietary intervention — patiromer is specifically employed to manage potassium, and a balanced potassium intake with continued patiromer monitoring is the appropriate approach, not extreme restriction.
• Option C: Option C is incorrect because high sodium intake actively antagonizes the efficacy of RAAS inhibition — this represents a fundamental pharmacological misunderstanding of the sodium-RAAS interaction.
• Option E: Option E is incorrect because near-zero dietary potassium intake is medically inappropriate and dangerous — hypokalemia is as harmful as hyperkalemia and is not the dietary target; patiromer is dosed to maintain potassium within a normal range on a moderate dietary potassium intake. CASE 5 — An 82-year-old man with CKD stage 3b (eGFR 36), isolated systolic hypertension (ISH), and no diabetes presents with BP 172/64 mmHg. He lives independently, is cognitively intact, and has a history of one fall 6 months ago. His current medications are amlodipine 5 mg daily only. He has no significant albuminuria (UACR 28 mg/g) and no history of cardiovascular events. He weighs 68 kg and his serum albumin is 3.2 g/L.

ANSWER: A

Rationale:

This patient exemplifies the challenge of applying population-level BP targets to complex elderly individuals. His combination of age 82, prior fall, a diastolic BP of 64 mmHg that already approaches the J-curve danger zone for coronary and cerebral perfusion (particularly relevant in elderly patients where cerebral autoregulation is impaired), low serum albumin suggesting frailty, and the absence of albuminuria or cardiovascular disease all argue for an individualized, cautious approach. A systolic target of 140–150 mmHg — rather than the standard less than 130/80 mmHg — reduces the risk of over-treatment and fall-related injury while still providing meaningful cardiovascular risk reduction compared to untreated hypertension. KDIGO 2021 explicitly acknowledges that frail elderly patients may not tolerate the BP targets achieved in clinical trials and recommends individualization. Any additions to his current regimen should begin at very low doses with close monitoring for orthostatic hypotension.

• Option B: Option B is incorrect because SPRINT, while it did include patients above age 75 and demonstrated benefit, specifically excluded patients with cognitive impairment, significant mobility limitations, or a prior fall — applying the less than 120 mmHg target to this frail elderly patient with a fall history is not appropriate and misapplies the SPRINT data.
• Option C: Option C is incorrect because completely withholding all antihypertensive therapy in a patient with systolic BP of 172 mmHg would leave him at high risk for stroke, cardiac events, and accelerated CKD progression — the goal is careful BP lowering, not abandonment of treatment.
• Option D: Option D is incorrect because RAAS inhibition is not mandated by CKD alone in the absence of albuminuria (UACR 28 mg/g is below the 30 mg/g threshold) — the indication for RAAS inhibition as first-line in CKD is specifically for patients with albuminuria above 30 mg/g; his BP can be managed with other agents first.
• Option E: Option E is incorrect because ISH in the elderly is primarily a result of arterial stiffness, not volume overload — furosemide is not the optimal agent for this mechanism and carries significant risk of volume depletion, orthostatic hypotension, and further fall risk in this frail patient.

ANSWER: C

Rationale:

Adding a RAAS inhibitor is the most pharmacologically elegant and clinically appropriate response to CCB-related peripheral edema in this patient. The mechanism of CCB-induced peripheral edema is precapillary arteriolar dilation without equivalent venodilation — this increases capillary hydrostatic pressure, driving fluid into the interstitium of dependent tissues. RAAS inhibitors, by dilating the efferent arteriole and reducing postcapillary resistance, partially counteract the increased capillary hydrostatic pressure gradient. The ACCOMPLISH trial demonstrated that the ACEi-CCB combination (benazepril plus amlodipine) was superior to ACEi-diuretic for cardiovascular outcomes, and clinical experience confirms that ACEi-CCB combinations produce less peripheral edema than CCB monotherapy. Additionally, this patient's borderline UACR of 28 mg/g — while currently below the 30 mg/g formal threshold — would be worth monitoring, and a low-dose RAAS inhibitor addition is pharmacologically rational.

• Option A: Option A is incorrect because peripheral edema is a class effect of all dihydropyridine CCBs, not specific to amlodipine — it relates to the degree of arteriolar versus venodilation produced by the class as a whole; nifedipine causes equivalent or greater peripheral edema than amlodipine.
• Option B: Option B is incorrect because while furosemide would reduce the edema symptomatically through natriuresis, it does not address the underlying mechanism (CCB-induced capillary pressure gradient) and adds diuretic risk in a frail elderly patient already with a low diastolic of 62 mmHg — a RAAS inhibitor addresses the cause rather than the symptom.
• Option D: Option D is incorrect because bisoprolol does not counteract CCB-mediated peripheral edema through sympathetic venous constriction — this mechanism is pharmacologically unsupported; beta-blockers do not specifically reverse the precapillary vasodilation responsible for CCB edema.
• Option E: Option E is incorrect in its mechanistic claim — lercanidipine does have a lower edema profile compared to other CCBs in some studies, but it is not negligible and does not achieve this through "intramembrane accumulation eliminating precapillary vasodilation"; lercanidipine's reduced edema is related to its balanced arteriolar/venodilatory profile, not the mechanism described.

ANSWER: D

Rationale:

Telmisartan is a pharmacokinetically appropriate choice for this elderly CKD patient for several reasons. It is eliminated primarily by biliary (hepatic) excretion and its pharmacokinetics are not significantly altered by declining renal function — unlike renally eliminated agents, its levels are more predictable in CKD. Its long half-life (approximately 24 hours) supports true once-daily dosing with consistent trough drug levels, which is particularly important in elderly patients whose adherence may be inconsistent. It is also the preferred ARB in hemodialysis patients for the same reasons (not dialyzable). Its PPARγ partial agonist activity, while modest, may provide some additional insulin-sensitizing metabolic benefit.

• Option A: Option A is incorrect because the half-life rationale is pharmacologically flawed — a shorter half-life is not inherently safer in the elderly; it means more frequent dosing and greater peak-trough fluctuation, neither of which is an advantage in this setting.
• Option B: Option B is incorrect because while valsartan has extensive evidence in heart failure (Val-HeFT, CHARM-Added), this does not make it the preferred ARB for CKD management — the evidence base for ARBs in CKD is class-wide, not specific to valsartan.
• Option C: Option C is incorrect because olmesartan's high AT1 receptor affinity does not specifically minimize systemic hypotension — receptor affinity determines duration and degree of blockade but does not selectively preserve systemic BP while maximizing efferent dilation; the claim is pharmacologically imprecise.
• Option E: Option E is incorrect because the IDNT evidence is ARB class evidence for diabetic nephropathy, not irbesartan-specific evidence applicable regardless of diabetes status and CKD etiology; using IDNT to mandate irbesartan over all other ARBs in non-diabetic CKD misapplies the trial data.

ANSWER: E

Rationale:

Amlodipine is a CYP3A4 substrate and grapefruit juice contains furanocoumarins (primarily bergamottin and 6',7'-dihydroxybergamottin) that irreversibly inhibit intestinal wall CYP3A4 through mechanism-based (suicide) inhibition. This reduces amlodipine's first-pass metabolism in the gut wall, increasing its oral bioavailability and AUC — studies have demonstrated increases in amlodipine AUC of 50–100% depending on the quantity and timing of grapefruit consumption. Because the inhibition is irreversible (mechanism-based), a single glass of grapefruit juice can affect drug absorption for 24–72 hours, making the "just avoid taking them at the same time" strategy pharmacologically inadequate — consistent avoidance or elimination is required. Clinically, the increased amlodipine exposure may enhance peripheral edema (already a concern in this patient) or cause symptomatic hypotension. Telmisartan is eliminated primarily by biliary glucuronidation via UGT enzymes and is not a CYP3A4 substrate — grapefruit juice does not affect its pharmacokinetics. Option C is pharmacologically accurate in mechanism but underestimates the magnitude — grapefruit-amlodipine interaction produces greater than a 20–30% increase in some studies and the irreversible nature of the inhibition is not conveyed, making E the more complete and accurate answer.

• Option A: Option A is incorrect because amlodipine is indeed a CYP3A4 substrate and the interaction is real and clinically relevant — dismissing it as non-existent is pharmacologically incorrect.
• Option B: Option B is incorrect because while grapefruit juice does inhibit hepatic OATP1B1/3 transporters (relevant for statins and some other drugs), telmisartan's interaction with grapefruit through this mechanism is not clinically established to produce the described 400% bioavailability increase; the primary grapefruit interaction of clinical relevance in this patient is with amlodipine via CYP3A4.
• Option D: Option D is incorrect because grapefruit does not induce P-glycoprotein — it inhibits P-gp in some contexts and primarily acts through CYP3A4 mechanism-based inhibition; naringenin is not a P-gp inducer. CASE 6 — A 51-year-old man with CKD stage 3a (eGFR 52), hypertension, and type 2 diabetes is referred for evaluation after his primary care physician noted a rising serum creatinine from 1.22 to 1.55 mg/dL over 4 months while on lisinopril 20 mg daily and amlodipine 10 mg daily. His BP is 128/76 mmHg. UACR was 460 mg/g 6 months ago and is now 180 mg/g (a 61% reduction). Potassium is 4.9 mEq/L. He has been on a high-dose ibuprofen 600 mg three times daily for chronic back pain for the past 6 months (prescribed by an orthopedist). He takes ibuprofen consistently.

ANSWER: B

Rationale:

This is the classic "triple whammy" nephrotoxic combination: an NSAID plus an ACE inhibitor plus a diuretic (or in this case NSAID plus ACE inhibitor, with the combined effect mimicking the triple whammy). The mechanism is pharmacologically specific and important. Renal prostaglandins — particularly PGE2 and PGI2 synthesized by the kidney — act as local vasodilators of the afferent arteriole, counterbalancing angiotensin II's efferent arteriolar constriction and maintaining GFR under conditions of RAAS activation. When ibuprofen inhibits COX enzymes, renal prostaglandin synthesis is suppressed, afferent arteriolar tone increases (constriction), and renal blood flow falls. Simultaneously, lisinopril is dilating the efferent arteriole, reducing the pressure gradient across the glomerulus from both ends simultaneously — afferent constriction (no PG vasodilation) and efferent dilation (ACE inhibition). This dual reduction in the transglomerular driving pressure produces a pharmacologically induced AKI that mimics bilateral renal artery stenosis. The most important immediate intervention is stopping ibuprofen and substituting acetaminophen for back pain. The favorable UACR response confirms that lisinopril is working appropriately.

• Option A: Option A is incorrect because 20 mg daily is within the standard dosing range for lisinopril's renoprotective indication — there is no maximum renoprotective dose threshold above which nephrotoxicity occurs; the creatinine rise has a pharmacological explanation related to the NSAID interaction.
• Option C: Option C is incorrect because amlodipine does not cause afferent arteriolar vasospasm through a tolerance mechanism — this is pharmacologically fabricated; amlodipine consistently dilates afferent arterioles and does not cause paradoxical calcium-mediated constriction with prolonged use.
• Option D: Option D is incorrect because a 27% creatinine rise over 4 months is not the expected rate of progression in well-managed diabetic CKD on RAAS inhibition — this is an acute change requiring investigation, not the natural history of the disease; and the NSAID use provides a clear reversible pharmacological explanation.
• Option E: Option E is incorrect because lisinopril is not significantly metabolized by CYP3A4 — it undergoes minimal hepatic metabolism and is primarily renally eliminated; the amlodipine-CYP3A4-lisinopril interaction described is pharmacologically inaccurate.

ANSWER: A

Rationale:

This patient meets all criteria for SGLT2 inhibitor addition. Type 2 diabetes plus CKD (eGFR 52) plus UACR 180 mg/g on background RAAS inhibition — this is precisely the population studied in DAPA-CKD (eGFR 25–75, UACR ≥200 mg/g) and CREDENCE (eGFR 30–90, UACR ≥300 mg/g). Even with the UACR now at 180 mg/g, this represents moderately elevated albuminuria in a patient with diabetic CKD who still has room for further renoprotective benefit from SGLT2 inhibitor therapy. KDIGO 2022 and ADA guidelines recommend SGLT2 inhibitors for patients with type 2 diabetes, CKD, and eGFR ≥20 — there is no minimum albuminuria threshold above which they are reserved; lower albuminuria is not a contraindication. The glucose-independent renoprotective mechanism (TGF restoration, reduced hyperfiltration, anti-fibrotic effects) provides benefit at eGFR 52.

• Option B: Option B is incorrect because no guideline specifies a minimum UACR of 300 mg/g for SGLT2 inhibitor use in type 2 diabetic CKD — the KDIGO 2022 recommendation applies across the UACR range studied, and waiting for albuminuria to worsen before adding a renoprotective agent is clinically counterproductive.
• Option C: Option C is incorrect because prior NSAID-related creatinine rise is not a contraindication to SGLT2 inhibitor use — the mechanisms are entirely different; NSAID nephrotoxicity results from COX inhibition and prostaglandin depletion, while the SGLT2 inhibitor eGFR dip results from TGF restoration; the two are not analogous and the prior episode does not contraindicate SGLT2 inhibitors.
• Option D: Option D is incorrect because SGLT2 inhibitor renoprotection in CKD is explicitly glucose-independent — it is not proportional to HbA1c and has no minimum HbA1c threshold; DAPA-CKD enrolled patients without diabetes at all.
• Option E: Option E is incorrect because SGLT2 inhibitor renoprotection is not restricted to eGFR below 45 — the DAPA-CKD and CREDENCE trials enrolled patients with eGFR up to 75 and 90 respectively, with consistent benefit across eGFR subgroups; initiating above eGFR 45 is both supported and appropriate.

ANSWER: E

Rationale:

This answer accurately captures the current state of evidence and mechanistic understanding of SGLT2 inhibitors versus GLP-1 receptor agonists in CKD. SGLT2 inhibitors have robust, dedicated renal outcome trial evidence (CREDENCE, DAPA-CKD, EMPA-KIDNEY) with well-characterized mechanisms — TGF restoration, hyperfiltration reduction, anti-inflammatory and anti-fibrotic effects independent of glycemic control. GLP-1 receptor agonists have demonstrated renal benefits in cardiovascular outcome trials (LEADER, SUSTAIN-6, REWIND) with secondary renal endpoints showing UACR reduction, and the dedicated renal outcome FLOW trial (semaglutide vs. placebo in type 2 diabetic CKD) published in 2024 demonstrated a 24% reduction in the primary kidney composite endpoint. GLP-1 receptor agonists likely work through distinct mechanisms including direct GLP-1R activation in podocytes and renal tubular cells reducing oxidative stress and inflammation, weight loss reducing adipose-driven renal inflammation, and systemic BP lowering. The two classes are complementary rather than competing, and combining them provides additive coverage of different pathophysiological pathways — appropriate for a patient with residual albuminuria and ongoing cardiovascular risk.

• Option A: Option A is incorrect because the two classes have different mechanisms — GLP-1 agonists do not reduce intraglomerular pressure through TGF restoration; their mechanisms are distinct.
• Option B: Option B is incorrect because the LEADER and SUSTAIN-6 renal endpoints were pre-specified secondary outcomes, not primary renal endpoints — comparing them to CREDENCE and DAPA-CKD as superior evidence misrepresents the evidence hierarchy; both classes have important renal evidence that should be viewed as complementary.
• Option C: Option C is incorrect because GLP-1 receptor agonists do have direct renal mechanisms beyond systemic BP lowering and weight loss — GLP-1R expression on glomerular and tubular cells mediates direct anti-inflammatory and anti-fibrotic effects; dismissing these as purely systemic hemodynamic misrepresents the pharmacology.
• Option D: Option D is incorrect because no guideline or trial data specify an albuminuria threshold below which SGLT2 inhibitors should be replaced by GLP-1 agonists; this is a fabricated recommendation.

ANSWER: C

Rationale:

The excellent response this patient has achieved — UACR 95 mg/g from a peak of 460 mg/g, stable eGFR, controlled glycemia and BP — reflects the active ongoing protective effects of his medication regimen, not cure of the underlying disease. Diabetic nephropathy is a chronic progressive condition driven by persistent hemodynamic, metabolic, inflammatory, and fibrotic mechanisms. Each of his renoprotective medications is actively suppressing one or more of these mechanisms: lisinopril continuously reduces intraglomerular pressure through efferent arteriolar dilation and suppresses RAAS-mediated fibrosis; dapagliflozin continuously restores tubuloglomerular feedback and prevents hyperfiltration; semaglutide continuously reduces weight-driven and GLP-1R-mediated renal inflammation. Discontinuing any of these would immediately restore the pathophysiological process it was suppressing. The analogy is antihypertensive therapy — the favorable BP response does not mean the underlying vascular biology has been cured; it reflects ongoing pharmacological suppression. Continuation of all evidence-based renoprotective therapy for the duration of the clinical indication is the standard of care, with discontinuation considered only if adverse effects emerge, the indication changes (e.g., eGFR becomes so low that benefit-risk shifts), or the patient makes an informed decision about drug burden.

• Option A: Option A is incorrect because RAAS inhibition in diabetic CKD is not discontinued when UACR normalizes — normalization reflects ongoing drug effect, and stopping the drug would cause UACR to return toward its previous level; the indication persists.
• Option B: Option B is incorrect because eGFR recovery above 60 on SGLT2 inhibitor therapy does not remove the CKD indication — the improved eGFR reflects the drug's protective effect and will decline if the drug is stopped; eGFR 60 is not a threshold above which SGLT2 inhibitors are no longer indicated.
• Option D: Option D is incorrect because semaglutide's renoprotective benefit is not exclusively glucose-dependent — GLP-1R-mediated direct renal effects persist regardless of HbA1c, and discontinuing based on glycemic target achievement misunderstands the drug's mechanisms.
• Option E: Option E is incorrect because a stepped withdrawal protocol based on order of addition is not a pharmacologically or clinically sound approach — the benefit of each agent is independent and ongoing; sequential withdrawal would progressively remove renoprotective coverage without clinical justification. CASE 7 — A 58-year-old man with CKD stage 4 (eGFR 19), hypertension, type 2 diabetes, and hyperuricemia presents with severe gout flare (left first metatarsophalangeal joint), uric acid 9.2 mg/dL, and BP 164/92 mmHg. Current medications: losartan 100 mg daily, torsemide 40 mg daily, amlodipine 10 mg daily, and metformin 500 mg daily (borderline eGFR for continuation). His creatinine is 3.5 mg/dL (stable), potassium 5.0 mEq/L, and UACR 620 mg/g.

ANSWER: D

Rationale:

Indomethacin — and all NSAIDs — are contraindicated in this patient with CKD stage 4. The triple whammy is fully assembled: an ARB (losartan) blocking efferent arteriolar angiotensin II-mediated tone, a loop diuretic (torsemide) reducing intravascular volume and activating the RAAS, and the proposed NSAID suppressing afferent arteriolar prostaglandin-mediated vasodilation. At baseline eGFR of 19, renal reserve is negligible — even a modest further reduction in GFR from this triple combination could precipitate acute-on-chronic renal failure requiring urgent dialysis initiation. The correct alternatives for acute gout in this setting are: colchicine at renally adjusted dose (significant dose reduction required at eGFR below 30 — colchicine 0.5 mg once or twice daily with extreme caution, as colchicine accumulates in CKD and carries risk of severe toxicity at normal doses); or intra-articular corticosteroid injection (most appropriate for monoarticular disease like this MTP flare — provides immediate local anti-inflammatory effect without systemic or renal risk); or systemic corticosteroids (prednisone 30–40 mg daily for 3–5 days) if intra-articular injection is not feasible.

• Option A: Option A is incorrect because there is no safe "short NSAID course" at eGFR 19 on the triple whammy combination — even 3 days of indomethacin with ARB plus loop diuretic at this GFR level carries high risk of serious AKI.
• Option B: Option B is incorrect because high-dose aspirin at anti-inflammatory doses has the same COX-inhibitory and prostaglandin-suppressive nephrotoxic mechanism as indomethacin — it is not a safe substitute in CKD.
• Option C: Option C is incorrect because doubling torsemide to increase diuresis in the setting of NSAID-induced afferent arteriolar constriction would worsen, not protect, renal perfusion — increasing diuresis in this context increases volume depletion and further activates RAAS, compounding the nephrotoxic triple whammy.
• Option E: Option E is incorrect because holding metformin removes the lactic acidosis concern but does nothing to address the NSAID-mediated nephrotoxicity — the renal hemodynamic risk from indomethacin at eGFR 19 remains unchanged regardless of metformin status.

ANSWER: E

Rationale:

Losartan has a well-established and pharmacologically documented uricosuric property that is unique among ARBs. The mechanism is direct inhibition of URAT1 (solute carrier SLC22A12) in the proximal tubule — a property of losartan's specific chemical structure (the carboxylate-imidazole moiety) that is not shared by other ARBs including valsartan, irbesartan, candesartan, or olmesartan. This URAT1 inhibition reduces proximal tubular urate reabsorption, increasing renal urate excretion and lowering serum uric acid by approximately 0.5–1.5 mg/dL. The clinical implication is that when an ARB is indicated in a hypertensive patient with hyperuricemia, losartan is preferred over other ARBs because it provides concurrent modest urate lowering. However, at eGFR 19, the reduced nephron mass substantially limits the tubular transport capacity available for urate excretion — URAT1 inhibition in a kidney with approximately 15–20% of normal nephron function cannot produce the same degree of uricosuria as in a patient with normal renal function. This patient requires additional dedicated urate-lowering therapy: allopurinol, a xanthine oxidase inhibitor, at a dose adjusted for eGFR below 30 (typically 50–100 mg daily, with careful titration to avoid allopurinol hypersensitivity syndrome). Option C is pharmacologically accurate but less complete than E — it correctly identifies the mechanism and the CKD limitation but omits the important management recommendation for additional urate-lowering therapy, which is the actionable clinical implication of this pharmacological knowledge.

• Option A: Option A is incorrect because losartan's uricosuric property is pharmacologically documented through URAT1 inhibition and is not attributable to dilutional effects from torsemide — the mechanism is specific and the clinical reduction in serum uric acid is reproducible in controlled studies.
• Option B: Option B is incorrect because losartan's uricosuric mechanism is URAT1 inhibition, not GLP-1 receptor agonism — GLP-1R has no established role in proximal tubular urate transport, and this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect because the uricosuric property is specifically losartan-unique and not a class effect of AT1 receptor blockade — other ARBs do not significantly inhibit URAT1 and do not produce the same degree of urate lowering.

ANSWER: B

Rationale:

Febuxostat is the appropriate alternative urate-lowering agent after allopurinol hypersensitivity. AHS is an allopurinol-specific immune reaction mediated by the allopurinol metabolite oxypurinol activating HLA-B*5801-restricted T-cell responses — it is not a class effect of xanthine oxidase inhibitors. Febuxostat is a structurally distinct, non-purine xanthine oxidase inhibitor with no cross-reactivity with allopurinol in hypersensitivity reactions. Dose adjustment for eGFR is less restrictive than allopurinol — febuxostat can be used at standard doses (40–80 mg daily) in CKD without the same degree of dose reduction required for allopurinol in advanced CKD. However, the FDA added a black box warning in 2019 regarding increased risk of cardiovascular death compared to allopurinol in the CARES trial (enrolling patients with established cardiovascular disease); since this patient has multiple cardiovascular risk factors (CKD stage 4, type 2 diabetes, hypertension, hyperuricemia), this warning requires clinical consideration — the benefit of febuxostat for recurrent gout management should be weighed against this cardiovascular risk signal, and the decision made with shared decision-making.

• Option A: Option A is incorrect because AHS with rash, fever, and facial edema is a serious hypersensitivity reaction — rechallenge with allopurinol is contraindicated regardless of dose, and desensitization is only considered for mild cutaneous reactions without systemic features; the presentation described carries risk of progression to Stevens-Johnson syndrome or DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms).
• Option C: Option C is incorrect because probenecid, a URAT1 inhibitor providing uricosuric therapy, is substantially ineffective in advanced CKD — at eGFR below 30 mL/min/1.73m2, there is insufficient nephron mass and tubular flow for probenecid to produce meaningful uricosuria; it is contraindicated in CKD stage 4.
• Option D: Option D is incorrect because colchicine is an anti-inflammatory agent that prevents gout flares by disrupting neutrophil-mediated crystal inflammation — it does not lower serum uric acid and is not a urate-lowering therapy; chronic colchicine does not substitute for xanthine oxidase inhibition in hyperuricemia management.
• Option E: Option E is incorrect because lesinurad was withdrawn from the global market in 2019; it is no longer available as a clinical therapeutic option.

ANSWER: C

Rationale:

As this patient approaches ESRD, his antihypertensive and metabolic regimen requires systematic reassessment across several dimensions. Metformin must be stopped — most guidelines recommend cessation at eGFR below 30 due to lactic acidosis risk; at eGFR 17 this is overdue and urgent. Torsemide remains important for residual volume management — maximizing residual urine output is a key goal in the pre-ESRD period. If a RAAS inhibitor is to be continued after dialysis initiation, switching from losartan to candesartan or telmisartan reduces the pharmacokinetic inconsistency caused by dialysis-related drug removal. Amlodipine requires no adjustment — it is hepatically metabolized and its pharmacokinetics are not significantly altered by declining renal function or uremia. The rising UACR likely reflects true CKD progression reducing residual renoprotective capacity, not a laboratory artifact. Dialysis modality planning matters — peritoneal dialysis better preserves residual renal function than hemodialysis, which has implications for how aggressively antihypertensive therapy should be managed.

• Option A: Option A is incorrect because pharmacological antihypertensive management remains essential in ESRD — ultrafiltration provides volume control but does not eliminate the need for pharmacological BP management, particularly between dialysis sessions when volume re-accumulates and RAAS activity persists.
• Option B: Option B is incorrect because while metformin cessation is the most urgent safety priority, it is not the only medication change required as ESRD approaches — option C provides the comprehensive reassessment this transition requires.
• Option D: Option D is incorrect because RAAS inhibitors retain cardiovascular benefit in ESRD even at very low eGFR, and the rising UACR at eGFR 17 represents genuine worsening proteinuria from CKD progression — it is not a laboratory artifact from concentrated urine; concentrated urine would increase UACR measurement (mg/g of creatinine) only if creatinine concentration fell disproportionately, which is not the mechanism described.
• Option E: Option E is incorrect because amlodipine is hepatically metabolized and its pharmacokinetics are not significantly altered by uremia — it does not accumulate to dangerous levels in CKD stage 5, and it is one of the most consistently used and safe antihypertensive agents across all stages of CKD including ESRD.